Opinion|Videos|October 14, 2024
Key Considerations for Adverse Event Management in mRCC: TKI Monotherapy vs ICI + TKI Combinations
Author(s)Rana R. McKay, MD
Panelists discuss how the management of adverse events differs between tyrosine kinase inhibitor (TKI) monotherapy and immune checkpoint inhibitor plus TKI (ICI+TKI) combinations, including any notable differences in adverse effect profiles among various ICI plus TKI regimens used in treating metastatic renal cell carcinoma.
Advertisement
Episodes in this series
- In your experience, how does the management of adverse events differ between tyrosine kinase inhibitor (TKI) monotherapy and immune checkpoint inhibitor (ICI) plus TKI combinations?
- Are there any notable differences between the various ICI plus TKI regimens?
Newsletter
Stay up to date on practice-changing data in community practice.
SubscribeAdvertisement
Related to this article
Daniel Heng, MD, discusses how belzutifan plus lenvatinib fills an unmet need after immunotherapy in RCC, with insights on managing hypoxia and anemia and on sequencing.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Breakthrough Status to Multi-Cancer Early Detection Blood Test
2
Epigenomic ctDNA Assay Predicts Recurrence in Resected Melanoma
3
Alpha-Emitting RYZ101 Meets Phase 3 PFS End Point in Advanced GEP-NETs
4
FDA Clears Phase 2 Trial of B7-H3 CAR T MT027 for Brain Metastases
5